Ponnazhagan S, Yoder M C, Srivastava A
Department of Medicine, Indiana University School of Medicine, Indianapolis 46202-5120, USA.
J Virol. 1997 Apr;71(4):3098-104. doi: 10.1128/JVI.71.4.3098-3104.1997.
Adeno-associated virus type 2 (AAV), a nonpathogenic human parvovirus, is gaining attention as a vector for potential use in human gene therapy. We and others have described AAV-mediated beta-globin gene transfer and expression in established human and murine erythroleukemia cell lines in vitro. However, successful AAV-mediated globin gene transduction of hematopoietic stem cells and long-term expression in vivo in progeny cells have not been documented. We report here that infection of murine hematopoietic bone marrow cells ex vivo with a recombinant AAV vector containing the genomic copy of a normal human globin gene followed by transplantation of these cells into lethally irradiated congenic mice resulted in efficient gene transfer into hematopoietic cells with long-term repopulating ability as detected by the presence of the human globin gene sequences in bone marrow and spleen in primary recipient mice for at least 6 months. Long-term expression of the human globin gene was also detected in bone marrow, but not in spleen, in primary recipient mice. Furthermore, in secondary-transplant experiments, we were also able to document the presence as well as expression of the transduced human globin gene in mouse bone marrow for up to 3 months. These results provide further support for potential use of the AAV-based vector system in gene therapy of human hemoglobinopathies in general and sickle-cell anemia and beta-thalassemia in particular.
2型腺相关病毒(AAV)是一种无致病性的人类细小病毒,作为一种可能用于人类基因治疗的载体正受到关注。我们和其他人已经描述了AAV介导的β-珠蛋白基因在已建立的人类和小鼠红白血病细胞系中的体外转移和表达。然而,尚未有文献记载AAV介导的造血干细胞珠蛋白基因转导及在体内子代细胞中的长期表达。我们在此报告,用含有正常人珠蛋白基因基因组拷贝的重组AAV载体体外感染小鼠造血骨髓细胞,然后将这些细胞移植到经致死剂量照射的同基因小鼠体内,结果显示能有效地将基因转移到具有长期重建能力的造血细胞中,这可通过在初代受体小鼠的骨髓和脾脏中检测到人珠蛋白基因序列来证实,且这种情况至少持续6个月。在初代受体小鼠的骨髓中也检测到了人珠蛋白基因的长期表达,但在脾脏中未检测到。此外,在二次移植实验中,我们还能证明转导的人珠蛋白基因在小鼠骨髓中的存在及表达,持续时间长达3个月。这些结果为基于AAV的载体系统在一般人类血红蛋白病尤其是镰状细胞贫血和β地中海贫血的基因治疗中的潜在应用提供了进一步支持。